NEW YORK, February 24 /PRNewswire/ -- THIS IS A MULTIVU REPORT. PARKINSON'S DISEASE AFFECTS AN ESTIMATED ONE AND A HALF MILLION AMERICANS. DURING THE FIRST-EVER WORLD PARKINSON CONGRESS, THE NATIONAL PARKINSON FOUNDATION AND SCHWARZ PHARMA CONVENED A PATIENT ROUNDTABLE DISCUSSION TO GAUGE TREATMENT SATISFACTION, COMMON SIDE EFFECTS AND THE IMPACT ON LOVED ONES.
RUTH HAGESTUEN, NATIONAL PARKINSON FOUNDATION:
"This opportunity allowed us to gain further insight into the patient experience and to find new solutions to help people with Parkinson and their families."
UNFORTUNATELY, THIS CONDITION HAS NO CURE AND THOUGH TREATMENTS ARE AVAILABLE, RESEARCH CONTINUES FOR INNOVATIVE AND EFFECTIVE THERAPIES. SCHWARZ PHARMA IS AT THE FOREFRONT OF RESEARCH WITH PRODUCTS FOR PARKINSON'S IN BOTH EARLY AND LATE STAGE DEVELOPMENT.
JAMES ALLEN, PARKINSON'S DISEASE PATIENT:
"As a person with Parkinson's, I am encouraged by the amount of research underway, and hope by sharing our experiences we've provided a better understanding of our needs."
FOR MORE INFORMATION, VISIT PARKINSON.ORG. I'M DANIELLE ADDAIR.
AUDIO PROVIDED BY: SCHWARZ PHARMA
Audio: http://www.prnewswire.com/broadcast/23734/consumer.htmlSCHWARZ PHARMACONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313, EXT. 3 OR EMAIL RADIO@MULTIVU.COM
Web site: http://WWW.PARKINSON.ORG/
